EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy

John M Burke iD, Nicholas Liu iD, Kristina S Yu iD, Michelle A Fanale iD, Andy Surinach iD, Carlos Flores iD, Julie Lisano iD, Tycel Phillips iD

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von John M Burke und 7 weiteren Autor:innen. Beteiligte Einrichtung: US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO, USA. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seagen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Since Food and Drug Administration approval of brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (A + CHP) as initial therapy for previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL), there has been limited research on real-world patient characteristics, treatment patterns, and clinical outcomes.

Methods

We retrospectively analyzed claims of patients with PTCL treated with frontline A + CHP or CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) using the Symphony Health Solutions database. Adults with International Classification of Diseases-9/10 PTCL diagnosis codes who initiated A + CHP or CHOP between November 2018 and July 2021 were included. A 1:1 propensity score matching analysis was performed that adjusted for potential confounders between groups.

Results

A total of 1344 patients were included (A + CHP, n = 749; CHOP, n = 595). Before matching, 61% were men; median age at index was 62 (A + CHP) and 69 (CHOP) years. The most common A + CHP-treated PTCL subtypes were systemic anaplastic large cell lymphoma (sALCL; 51%), PTCL-not otherwise specified (NOS; 30%), and angioimmunoblastic T-cell lymphoma (AITL; 12%); the most common CHOP-treated subtypes were PTCL-NOS (51%) and AITL (19%). After matching, similar proportions of patients treated with A + CHP and CHOP received granulocyte colony-stimulating factor (89% vs. 86%, P = .3). Fewer patients treated with A + CHP received subsequent therapy than CHOP overall (20% vs. 30%, P < .001) and specifically with the sALCL subtype (15% vs. 28%, P = .025).

Conclusions

Characteristics and management of this real-world PTCL population who were older and had a higher comorbidity burden than that in the ECHELON-2 trial demonstrate the importance of retrospective studies when assessing the impact of new regimens on clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, PeripheralAdultMaleHumansFemaleBrentuximab VedotinRetrospective StudiesPrednisonePropensity ScoreAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicin

Stichwörter der Autor:innen

brentuximab vedotinclaims analysisperipheral T-cell lymphomareal-world evidencetreatment patterns

Substanzen

Brentuximab VedotinPrednisoneCyclophosphamideDoxorubicin

Autor:innen und Institutionen

  • US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO, USA.
  • Health Economics and Outcomes Research, Seagen Inc., Bothell, WA, USA.
  • Real-World Evidence Analytics, Genesis Research, Hoboken, NJ, USA.
  • Evidence Strategy, Genesis Research, Hoboken, NJ, USA.
  • Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.

ORCID-Profile: John M Burke, Nicholas Liu, Kristina S Yu, Michelle A Fanale, Andy Surinach, Carlos Flores, Julie Lisano, Tycel Phillips

Förderung

  • Seagen Inc

Zitieren

APA

Burke, J. M., Liu, N., Yu, K. S., Fanale, M. A., Surinach, A., Flores, C., Lisano, J., & Phillips, T. (2023). Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy. The Oncologist. https://doi.org/10.1093/oncolo/oyad068

Vancouver

Burke JM, Liu N, Yu KS, Fanale MA, Surinach A, Flores C, et al. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy. The Oncologist. 2023. doi:10.1093/oncolo/oyad068

BibTeX
@article{Burke2023,
  author = {Burke, John M and Liu, Nicholas and Yu, Kristina S and Fanale, Michelle A and Surinach, Andy and Flores, Carlos and Lisano, Julie and Phillips, Tycel},
  title = {Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad068}
}
Kostenlos starten →